Bausch + Lomb announces positive phase 3 data for sub-micron loteprednol etabonate

Bausch + Lomb announced that its twice-daily sub-micron loteprednol etabonate was superior to placebo in eliminating inflammation and pain after cataract surgery.If approved, the novel gel will be the first twice-daily ophthalmic steroid, according to a company press release.